HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining haemostasis in a dose-dependent manner

Back

ESC Professional Premium Access

HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining haemostasis in a dose-dependent manner

Session: Current and novel antiplatelet therapy in cardiovascular disease

Topic: Antiplatelet Drugs

Speaker: Professor M. Holinstat (Ann Arbor, US)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Professor Michael Holinstat

University of Michigan, Ann Arbor (United States of America)

0 follower

5 more presentations in this session

Superiority of CS585 as a selective prostacyclin receptor agonist in prevention of thrombosis

Speaker: Ms L. Stanger (Ann Arbor, US)

Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease

Speaker: Doctor M. Galli (Rome, IT)

Variability of the antithrombotic effect of acetylsalicylic acid with the administration of different dosages: reality or myth?

Speaker: Doctor J. Lima Lopes (Amadora, PT)

Antiplatelet effect of acetylsalicylic acid in patients early after cardiac valve surgery: comparative investigation of the impairment of platelet inhibition by dipyrone versus acetaminophen

Speaker: Professor D. Trenk (Bad Krozingen, DE)

CYP2C19 genotype prevalence and association with recurrent myocardial infarction in British-South Asians treated with clopidogrel

Speaker: Doctor E. Magavern (London, GB)

Access the full session

Current and novel antiplatelet therapy in cardiovascular disease

Speakers: Professor M. Holinstat, Ms L. Stanger, Doctor M. Galli, Doctor J. Lima Lopes, Professor D. Trenk...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining haemostasis in a dose-dependent manner

About the speaker

Professor Michael Holinstat

5 more presentations in this session

Superiority of CS585 as a selective prostacyclin receptor agonist in prevention of thrombosis

Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease

Variability of the antithrombotic effect of acetylsalicylic acid with the administration of different dosages: reality or myth?

Antiplatelet effect of acetylsalicylic acid in patients early after cardiac valve surgery: comparative investigation of the impairment of platelet inhibition by dipyrone versus acetaminophen

CYP2C19 genotype prevalence and association with recurrent myocardial infarction in British-South Asians treated with clopidogrel

Access the full session

Current and novel antiplatelet therapy in cardiovascular disease

About the event

ESC Congress 2023

ESC 365 is supported by